Commentary
To investigate incidence and predictors of NAFLD and NASH by employing noninvasive testing in liver transplant recipients (i.e. controlled attenuation parameter and cytokeratin 18), A. Alhinai et al. (McGill University, Montreal, Canada) prospectively recruited 40 consecutive adult patients who received liver transplant at the McGill University Health Centre between 2015-2018. During a median follow-up of 16.8 mo, 63% and 48% of patients developed NAFLD and NASH, respectively. As highlighted by the authors, “close follow-up and nutritional counselling should be planned in overweight patients.”
